SCHEMBL24919969

SCHEMBL24919969

C[Si](C)(C)C#Cc1ccc(Sc2ccccccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.53
MAOB P27338 4/20 0.53
ALDH1A1 P00352 4/20 0.41
HPGD P15428 3/20 0.41
SLC6A4 P31645 1/20 0.38
APP P05067 1/20 0.37
GABRA1 P14867 2/20 0.37
GABRG2 P18507 2/20 0.37
GABRB3 P28472 2/20 0.37
GABRA5 P31644 2/20 0.37
GABRA3 P34903 2/20 0.37
GABRA2 P47869 2/20 0.37
CYP1A2 P05177 3/20 0.36
CYP1A1 P04798 1/20 0.36
CYP1B1 Q16678 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712499 0.83 APP (0.57) ALDH1A1HPGDAPPCYP1A2CYP1A1
SCHEMBL563613 0.83 APP (0.55) ALDH1A1HPGDAPPCYP1A2CYP1A1
Diphenylacetylene SCHEMBL3842452 0.81 APP (0.60) ALDH1A1HPGDAPPCYP1A2NPC1
SCHEMBL1306384 0.80 GABRA1 (0.38) ALDH1A1HPGDAPPGABRA1GABRG2
SCHEMBL24919970 0.79 CYP1A1 (0.59) MAOAMAOBALDH1A1HPGDSLC6A4
SCHEMBL12477508 0.79 CYP1A2 (0.59) ALDH1A1HPGDAPPGABRA1GABRG2
SCHEMBL25798906 0.79 ACACB (0.40) MAOAMAOBALDH1A1SLC6A4GABRA1
SCHEMBL1306505 0.78 APP (0.41) ALDH1A1HPGDAPPGABRA1GABRG2
SCHEMBL10706841 0.75 MLYCD (0.39) MAOAMAOBGABRA1GABRG2GABRB3
SCHEMBL29169050 0.74 SLC6A4 (0.38) MAOASLC6A4GABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230014855-A1 MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF FORESEE PHARMACEUTICALS USA, INC. 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230014855-A1 MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF MMP12, MMP1, MMP11 MAOA 2243/4885MAOB 2258/4885ALDH1A1 2785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.